Clinical analysis of rituximab-induced interstitial pneumonia

Huijuan Lv, Ling Dong, Wei Li, Yun Hou, Zheng Song, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianming Liu, Huaqing Wang, Huilai Zhang, Kai Fu

Research output: Contribution to journalArticle

Abstract

Objective: To identify whether the use of rituximab predisposed to interstitial pneumonia (IP) after treatment of B cell nonHodgkin's lymphoma (B-NHL) with the chemotherapy and immunochemothrapy and to assess the clinical features and treatment of IP.Methods: A clinical study was conducted on 266 cases of CD20+ B-NHL patients with CHOP-like or RCHOP-like therapeutic regimen from January 2010 to May 2015. The cases were divided into rituximab-containing chemotherapy group and chemotherapy group. We analyzed the relationship between the development of IP and the use of rituximab. The IP related clinical features were also reviewed.Results: The incidence of IP in the rituximab-containing chemotherapy group was significantly higher compared with the incidence in the chemotherapy group. The IP-related factors include age>60, male, elevated absolute lymphocyte count (ALC), diabetes, and diffuse larpe B-cell lymphoma (DLBCL) subtype. By multivariate analysis, elevated ALC, diabetes, DLBCL subtype, and addition of rituximab were revealed as significant factors for an elevated risk of IP. Conclusion: The incidence of IP was higher in patients with CD20+ BNHL receiving rituximab-containing chemotherapy; this result may be related to immune disorders. Corticosteroids and antifungal therapy can effectively relieve the patients' symptoms.

Original languageEnglish (US)
Pages (from-to)291-297
Number of pages7
JournalChinese Journal of Clinical Oncology
Volume43
Issue number7
DOIs
StatePublished - Jan 1 2016

Fingerprint

Interstitial Lung Diseases
B-Cell Lymphoma
Drug Therapy
Lymphocyte Count
Non-Hodgkin's Lymphoma
Incidence
Rituximab
Age Factors
Immune System Diseases
Therapeutics
Adrenal Cortex Hormones
Multivariate Analysis

Keywords

  • B cell non-Hodgkin'slymphoma
  • Interstitial pneumonia
  • Risk factor
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical analysis of rituximab-induced interstitial pneumonia. / Lv, Huijuan; Dong, Ling; Li, Wei; Hou, Yun; Song, Zheng; Li, Lanfang; Qiu, Lihua; Qian, Zhengzi; Zhou, Shiyong; Liu, Xianming; Wang, Huaqing; Zhang, Huilai; Fu, Kai.

In: Chinese Journal of Clinical Oncology, Vol. 43, No. 7, 01.01.2016, p. 291-297.

Research output: Contribution to journalArticle

Lv, H, Dong, L, Li, W, Hou, Y, Song, Z, Li, L, Qiu, L, Qian, Z, Zhou, S, Liu, X, Wang, H, Zhang, H & Fu, K 2016, 'Clinical analysis of rituximab-induced interstitial pneumonia', Chinese Journal of Clinical Oncology, vol. 43, no. 7, pp. 291-297. https://doi.org/10.3969/j.issn.1000-8179.2016.07.284
Lv, Huijuan ; Dong, Ling ; Li, Wei ; Hou, Yun ; Song, Zheng ; Li, Lanfang ; Qiu, Lihua ; Qian, Zhengzi ; Zhou, Shiyong ; Liu, Xianming ; Wang, Huaqing ; Zhang, Huilai ; Fu, Kai. / Clinical analysis of rituximab-induced interstitial pneumonia. In: Chinese Journal of Clinical Oncology. 2016 ; Vol. 43, No. 7. pp. 291-297.
@article{110f6c36b02f46c8833e161e171bef80,
title = "Clinical analysis of rituximab-induced interstitial pneumonia",
abstract = "Objective: To identify whether the use of rituximab predisposed to interstitial pneumonia (IP) after treatment of B cell nonHodgkin's lymphoma (B-NHL) with the chemotherapy and immunochemothrapy and to assess the clinical features and treatment of IP.Methods: A clinical study was conducted on 266 cases of CD20+ B-NHL patients with CHOP-like or RCHOP-like therapeutic regimen from January 2010 to May 2015. The cases were divided into rituximab-containing chemotherapy group and chemotherapy group. We analyzed the relationship between the development of IP and the use of rituximab. The IP related clinical features were also reviewed.Results: The incidence of IP in the rituximab-containing chemotherapy group was significantly higher compared with the incidence in the chemotherapy group. The IP-related factors include age>60, male, elevated absolute lymphocyte count (ALC), diabetes, and diffuse larpe B-cell lymphoma (DLBCL) subtype. By multivariate analysis, elevated ALC, diabetes, DLBCL subtype, and addition of rituximab were revealed as significant factors for an elevated risk of IP. Conclusion: The incidence of IP was higher in patients with CD20+ BNHL receiving rituximab-containing chemotherapy; this result may be related to immune disorders. Corticosteroids and antifungal therapy can effectively relieve the patients' symptoms.",
keywords = "B cell non-Hodgkin'slymphoma, Interstitial pneumonia, Risk factor, Rituximab, Treatment",
author = "Huijuan Lv and Ling Dong and Wei Li and Yun Hou and Zheng Song and Lanfang Li and Lihua Qiu and Zhengzi Qian and Shiyong Zhou and Xianming Liu and Huaqing Wang and Huilai Zhang and Kai Fu",
year = "2016",
month = "1",
day = "1",
doi = "10.3969/j.issn.1000-8179.2016.07.284",
language = "English (US)",
volume = "43",
pages = "291--297",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "7",

}

TY - JOUR

T1 - Clinical analysis of rituximab-induced interstitial pneumonia

AU - Lv, Huijuan

AU - Dong, Ling

AU - Li, Wei

AU - Hou, Yun

AU - Song, Zheng

AU - Li, Lanfang

AU - Qiu, Lihua

AU - Qian, Zhengzi

AU - Zhou, Shiyong

AU - Liu, Xianming

AU - Wang, Huaqing

AU - Zhang, Huilai

AU - Fu, Kai

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: To identify whether the use of rituximab predisposed to interstitial pneumonia (IP) after treatment of B cell nonHodgkin's lymphoma (B-NHL) with the chemotherapy and immunochemothrapy and to assess the clinical features and treatment of IP.Methods: A clinical study was conducted on 266 cases of CD20+ B-NHL patients with CHOP-like or RCHOP-like therapeutic regimen from January 2010 to May 2015. The cases were divided into rituximab-containing chemotherapy group and chemotherapy group. We analyzed the relationship between the development of IP and the use of rituximab. The IP related clinical features were also reviewed.Results: The incidence of IP in the rituximab-containing chemotherapy group was significantly higher compared with the incidence in the chemotherapy group. The IP-related factors include age>60, male, elevated absolute lymphocyte count (ALC), diabetes, and diffuse larpe B-cell lymphoma (DLBCL) subtype. By multivariate analysis, elevated ALC, diabetes, DLBCL subtype, and addition of rituximab were revealed as significant factors for an elevated risk of IP. Conclusion: The incidence of IP was higher in patients with CD20+ BNHL receiving rituximab-containing chemotherapy; this result may be related to immune disorders. Corticosteroids and antifungal therapy can effectively relieve the patients' symptoms.

AB - Objective: To identify whether the use of rituximab predisposed to interstitial pneumonia (IP) after treatment of B cell nonHodgkin's lymphoma (B-NHL) with the chemotherapy and immunochemothrapy and to assess the clinical features and treatment of IP.Methods: A clinical study was conducted on 266 cases of CD20+ B-NHL patients with CHOP-like or RCHOP-like therapeutic regimen from January 2010 to May 2015. The cases were divided into rituximab-containing chemotherapy group and chemotherapy group. We analyzed the relationship between the development of IP and the use of rituximab. The IP related clinical features were also reviewed.Results: The incidence of IP in the rituximab-containing chemotherapy group was significantly higher compared with the incidence in the chemotherapy group. The IP-related factors include age>60, male, elevated absolute lymphocyte count (ALC), diabetes, and diffuse larpe B-cell lymphoma (DLBCL) subtype. By multivariate analysis, elevated ALC, diabetes, DLBCL subtype, and addition of rituximab were revealed as significant factors for an elevated risk of IP. Conclusion: The incidence of IP was higher in patients with CD20+ BNHL receiving rituximab-containing chemotherapy; this result may be related to immune disorders. Corticosteroids and antifungal therapy can effectively relieve the patients' symptoms.

KW - B cell non-Hodgkin'slymphoma

KW - Interstitial pneumonia

KW - Risk factor

KW - Rituximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85019115682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019115682&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2016.07.284

DO - 10.3969/j.issn.1000-8179.2016.07.284

M3 - Article

AN - SCOPUS:85019115682

VL - 43

SP - 291

EP - 297

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 7

ER -